Trius Therapeutics to Present Data From Tedizolid Clinical Studies at IDWeek Conference

SAN DIEGO, Oct. 16, 2012 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX) announced today that the results of multiple studies from its lead antibiotic drug candidate, tedizolid phosphate, will appear in poster presentations at the inaugural IDWeek conference, a joint meeting of the Infectious Disease Society of America, the Society for Healthcare Epidemiology of America, the HIV Medicine Association, and the Pediatric Infectious Disease Society, in San Diego from October 17th to 21st. Two tedizolid-related posters have been accepted for presentation, including clinical and safety results.

The clinical abstracts examine the hematological effect of tedizolid and linezolid in patients with acute bacterial skin and skin structure infections (ABSSSI), as well as pharmacokinetics in an adolescent population. The abstracts include one poster presentation from the ESTABLISH 1 trial (formerly known as the TR-701-112 trial) summarizing the detailed hematological results from Trius' first Phase 3 trial of tedizolid in patients with ABSSSI. This marks the first time these data are being presented at a major medical meeting. Top-line results for the ESTABLISH 1 trial, reported in December 2011, showed that tedizolid achieved all primary and secondary efficacy outcomes after a short course of therapy, and showed significant improvements in key safety and tolerability measurements in the complete study population versus the comparator linezolid (Zyvox®). This is the first of two registrational studies for tedizolid.

Tedizolid is the Company's lead product candidate. It is a once daily, IV and orally administered oxazolidinone being developed for the treatment of serious gram-positive infections, including those caused by methicillin-resistant Staphylococcus aureus (MRSA).

The presentations are as follows:

Friday, October 19th

Poster Session – Antimicrobial Chemotherapy (12:30 p.m. – 2:00 p.m.)

  • 789: A Comparative Evaluation of Adverse Platelet Outcomes among Patients with Acute Bacterial Skin and Skin Structure Infections Receiving Tedizolid Phosphate and Linezolid; T. Lodise, C. De Anda, E. Fang.

Saturday, October 20th

Poster Session – PK/PD Studies (12:30 p.m. – 2:00 p.m.)

  • 1640: Population Pharmacokinetics (PK) of Oral and Intravenously Administered Tedizolid Phosphate in Adolescent Patients; E. Capparelli, S. Flanagan, J. Bradley, A. Arrieta, R. Jacobs, K. A. Munoz, H. Dreskin, E. Fang, P. Prokocimer

Copies of these posters will be available on the Trius website following the IDWeek meeting:

About Trius Therapeutics

Trius Therapeutics, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. The Company's lead investigational drug, tedizolid phosphate, is a once daily, IV and orally administered oxazolidinone in Phase 3 clinical development for the treatment of ABSSSI. Trius has two Special Protocol Assessments with the FDA for its two Phase 3 ABSSSI trials and has partnered with Bayer HealthCare for the development and commercialization of tedizolid in Asia and Emerging Markets. In addition to the Company's tedizolid clinical program, Trius has initiated IND-enabling studies for its Gyrase-B/ParE development candidate. This dual-inhibitor agent has potent activity against gram-negative bacterial pathogens, including multi-drug resistant strains of E. coli, Klebsiella, Acinetobacter and Pseudomonas. The Gyrase-B program is one of the two preclinical programs supported by federal contracts. For more information, visit

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding Trius' ability to meet its future financing needs and successfully complete its ongoing clinical trials and development programs and transition into commercialization. Risks that contribute to the uncertain nature of the forward-looking statements include: the accuracy of Trius' estimates regarding expenses, future revenues and capital requirements; the success and timing of Trius' preclinical studies and clinical trials; regulatory developments in the United States and foreign countries; changes in Trius' plans to develop and commercialize its product candidates; Trius' ability to obtain additional financing; Trius' ability to obtain and maintain intellectual property protection for its product candidates; and the loss of key scientific or management personnel. These and other risks and uncertainties are described more fully in Trius' most recently filed SEC documents, including its Form 10-K, Forms 10-Q and other documents filed with the United States Securities and Exchange Commission, including those factors discussed under the caption "Risk Factors" in such filings. All forward-looking statements contained in this press release speak only as of the date on which they were made. Trius undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

CONTACT: Media Contacts: Laura Kempke/Andrew Law MSLGROUP 781-684-0770 Investor Relations Contact: Stefan Loren Westwicke Partners, LLC 443-213-0507 sloren@westwicke.comSource:Trius Therapeutics, Inc.